Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study

Эффективность и безопасность тирзепатида у взрослых с сахарным диабетом 1 типа: наблюдательное исследование, подтверждающее концепцию
Halis Kaan Aktürk, Fran Dong, Janet K. Snell‐Bergeon, Kagan Ege Karakus, Viral N. Shah
2024-02-05

Continuous glucose monitoringHemoglobin A1cTime in rangeTirzepatideType 1 diabetes
Background: Tirzepatide is approved by the United States Food and Drug Administration (FDA) for the management of type 2 diabetes. The efficacy and safety of this drug have not been studied in people with type 1 diabetes (T1D). Methods: In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months. Primary outcomes were reduction in HbA1c and percent change in body weight and secondary outcomes were change in CGM metrics and BMI over 8 months from baseline. Results: The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m 2 . There was significant reduction in HbA1c by 0.45% at 3 months and 0.59% at 8 months, and a significant reduction in body weight by 3.4%, 10.5%, and 10.1% at 3, 6, and 8 months after starting tirzepatide. Time in target range (TIR = 70-180 mg/dL) and time in tight target range (TITR = 70-140 mg/dL) increased (+12.6%, P = .002; +10.7%, P = .0016, respectively) and time above range (TAR >180 mg/dL) decreased (−12.6%, P = .002) at 3 months, and these changes were sustained over 8 months. The drug was relatively safe and well tolerated with only 2 patients discontinuing the medication. Conclusions: Tirzepatide significantly reduced HbA1c and body weight in adults with T1D. A randomized controlled trial is needed to establish efficacy and safety of this drug in T1D.
1
At 3 months, time in target range increased by 12.6%, time in tight target range increased by 10.7%, and time above range decreased by 12.6%; these improvements persisted through 8 months.
2
In a single-center retrospective study of 26 adults with type 1 diabetes, tirzepatide reduced HbA1c by 0.45% at 3 months and 0.59% at 8 months.
3
Randomized controlled trials are needed to confirm tirzepatide’s efficacy and safety in people with type 1 diabetes.
4
Tirzepatide reduced body weight by 3.4%, 10.5%, and 10.1% at 3, 6, and 8 months, respectively.
5
Tirzepatide was relatively well tolerated, with only 2 of 26 participants discontinuing treatment.

Tirzepatide treatment in adults with type 1 diabetes

Tirzepatide-associated changes in glycemic control, body weight, BMI, continuous glucose monitoring metrics, and treatment safety over 8 months

Publication Details
Publication Date
2024-02-05
Journal
Publisher
ISSN
Cited by
67
Access Type
Author Information
Authors
Halis Kaan Aktürk
Fran Dong
Janet K. Snell‐Bergeon
Kagan Ege Karakus
Viral N. Shah
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%